Early data on the safety and tolerability of combination venetoclax and cytarabine or cytarabine/idarubicin were presented at ASCO 2019.
A randomized phase II trial investigated whether adding CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia.
Researchers tested simultaneous vs delayed rituximab with cladribine in patients with hairy cell leukemia.
Maintenance rituximab was tested in patients with diffuse large B-cell lymphoma who achieved complete remission after R-CHOP.
Updated results from ENESTop show patients with CML remain in treatment-free remission after stopping nilotinib.
The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial was maintained regardless of the presence of several common co-mutations.
Five-year follow-up of the phase III COMPLEMENT 1 study focused on the efficacy with respect to overall and progression-free survival.
The MAGNIFY phase IIIb trial looked at the efficacy and safety of lenalidomide combined with rituximab in relapsed/refractory indolent non-Hodgkin lymphoma.
Researchers studied the Fc-enhanced, humanized anti-CD19 antibody MOR208 combined with lenalidomide in relapsed/refractory large B-cell lymphoma.
Daratumumab + European Standard Yields Clinical Benefit in Transplant Eligible, Newly Diagnosed Myeloma
New data from the CASSIOPEIA trial evaluated the use of daratumumab in addition to bortezomib/thalidomide/dexamethasone after ASCT in multiple myeloma.